Oxford Biomedica is delivering life changing gene therapies to patients. Our LentiVector platform is broadly accepted by big Pharma and biotech partners for efficient, permanent and cost effective delivery of genes to cells. With over 550 employees and >200,000 sqft facilities in the UK, we have the end-to-end capabilities in discovery, development, clinical and commercial GMP manufacturing of viral vectors to accelerate and derisk development of cell and gene therapies